Quotient: discovering targets via ultra-sensitive somatic genotyping 

Flagship’s newest company, Quotient, is betting that ultra-sensitive genotyping of the diversity of somatic mutations within individuals will allow it to discover therapeutic targets without needing whole-genome sequences from large populations of people. The idea is that the genetic diversity within an individual can explain why some of their cells are more or less susceptible to disease.

Flagship Pioneering Origination Partner Jacob Rubens, who is serving as president of Quotient Therapeutics Inc., told BioCentury that Flagship made its seed investment in the company in 2021, forming what it calls a “protocompany,” then completed a series A round in 2022, for a total investment of $50 million...